A prospective study of primary metastatic renal cell carcinoma treated with immunecheckpoint inhibitors and cytoreductive nephrectomy vs primary tumour in place

A prospective study of primary metastatic renal cell carcinoma treated with immunecheckpoint inhibitors and cytoreductive nephrectomy vs primary tumour in place - PrimerX

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON57224

Enrollment

750

Registered

2024-03-14

Start date

2023-05-01

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma renal malignancy

Interventions

Cytoreductive nephrectomy

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Histologically confirmed diagnosis of metastatic renal cell carcinoma of intermediate to poor risk treated with immunecheckpoint inhibitors

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
complications after cytoreductive nephrectomy	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)